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Convergent functional genomics (CFG) is a translational methodology that integrates in a Bayesian fashion multiple
lines of evidence from studies in human and animal models to get a better understanding of the genetics of a
disease or pathological behavior. Here the integration of data sets that derive from forward genetics in animals and
genetic association studies including genome wide association studies (GWAS) in humans is described for addictive
behavior. The aim of forward genetics in animals and association studies in humans is to identify mutations
(e.g. SNPs) that produce a certain phenotype; i.e. “from phenotype to genotype”. Most powerful in terms of forward
genetics is combined quantitative trait loci (QTL) analysis and gene expression profiling in recombinant inbreed
rodent lines or genetically selected animals for a specific phenotype, e.g. high vs. low drug consumption. By
Bayesian scoring genomic information from forward genetics in animals is then combined with human GWAS data
on a similar addiction-relevant phenotype. This integrative approach generates a robust candidate gene list that has
to be functionally validated by means of reverse genetics in animals; i.e. “from genotype to phenotype”. It is proposed
that studying addiction relevant phenotypes and endophenotypes by this CFG approach will allow a better
determination of the genetics of addictive behavior.
Keywords: Substance use disorders; Alcohol addiction; Behavioral addictions; Endophenotypes; QTL analysis;
Transcriptomic analysis; GWAS; Transgenic animal modelsReview
According to the World Health Organization (WHO),
approx. 2 billion people drink alcohol, 1.3 billion people
use tobacco, and almost 200 million people use illicit
drugs. Many of those alcohol, tobacco and drug users
continue taking these substances despite developing severe
health and social problems and a substantial proportion
become addicted. Drug addictiona is defined as a patho-
logical behavioral syndrome with compulsive drug use,
craving, and relapses that can occur even after years of
abstinence. There are different classes of substances includ-
ing alcohol, nicotine, cannabis, opiates, and stimulants. All
of them can lead to addictive behavior.
Very recently, the term addiction has been applied to
a range of problematic behaviors such as pathologicalCorrespondence: rainer.spanagel@zi-mannheim.de
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in any medium, provided the original work is pgambling and pathological internet use, to mention only a
few. Consequently, the new psychiatric classification
system DSM-5 for the first time attempts to categorize
substance use disorders vs. so-called behavioral addictions.
The DSM-V committee decided to accept “Gambling
Disorder” (or pathological gambling) as an addiction and
to put “Internet Use Disorder” into the category, where
more research is needed.
One fundamental question in addiction research is:
What are the genetic factors underlying this pathological
behavior and to which extent do alcohol, nicotine, opiate,
cannabis, and cocaine addiction and also behavioral addic-
tions share genetic mechanisms? Knowledge about distinct
and shared genetic mechanisms of substance use disorders
(SUDs) has important implications for diagnosis, treatment,
addiction theories and future research.pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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behavioral addictions
Twin, adoption and sibling studies have shown that
genetic influences are directly responsible for some of the
inter-individual differences observed in the predisposition
to addictive behavior. A meta-analysis that included several
sets of ten thousands of monozygotic and dizygotic twin
pairs, estimated a heritability of different drug addictions
to lie at around 40-70% (Goldman 2005). There have also
been two major twin studies of pathological gambling with
consistent evidence for heritable variation (50%) (Slutske
et al. 2010; Agrawal et al. 2012). Typically any form of
addiction is a complex disorder that shows no obvious
Mendelian transmission pattern and provides no evidence
for main gene effects. Thus the contribution of single genes
to the clinical phenotype, perhaps with the exception of
some rare variants (Malhotra and Sebat 2012), is rather
small.
Does a genetic overlap exist between different drugs of
abuse? Family studies have revealed that across several
drug classes (opioids, cocaine, cannabis, nicotine, alcohol),
the offspring of substance abusers are at 2 to 8-fold in-
creased risk to develop an addictive behavior (Merikangas
et al. 1998; Merikangas and McClair 2012). A third of the
variance in risk for nicotine and cannabis addiction,
and about 40% of the variance in alcohol addiction is
accounted for by additive genetic factors common to all
three disorders (Xian et al. 2008; Palmer et al. 2012). Fur-
thermore, it has been shown that there also exits a genetic
overlap between drug and behavioral addictions; e.g. 20%
of the genetic risk for pathological gambling has been
shown to be accounted for by the genetic risk for alcohol
addiction (Slutske et al. 2000; Lobo and Kennedy 2009).
Technological advancements such as next generation
sequencing and systematic genome wide association studies
(GWASs) play a crucial role in candidate gene discovery
today. These technological developments also led to a
sharp increase in publications on the genetics of addiction
in the last decade (Helinski and Spanagel 2011) and will
help to identify shared and distinct gene patterns associated
with different drug addictions and behavioral addictions.
Rare functional exonic variants can now be efficiently
genotyped, allowing exome-wide association tests but
detection of individual variants may require very large
samples (Vrieze et al. 2013). Nevertheless, in a quiet small
sample of cases and controls, deep resequencing of
glutamate system genes allowed in a very recent study
the identification of several rare variants affecting risk of
opioid dependence demonstrating that depending on the
hypothesis exome sequencing can yield significant results
even in less than 1000 affected cases (Xie et al. 2013).
GWASs play a crucial role in candidate gene discovery
today and have been successfully applied to addiction
research, especially in nicotine and alcohol addiction wheremeta-analyses with over 80,000 individuals of European
ancestry are available today.
GWAS of smoking behavior and nicotine addiction
have produced consistent and compelling genetic evidence
for association (Bierut et al. 2008). The strongest genetic
contribution to nicotine addiction comes from variation
in the nicotinic acetylcholine receptor subunits. The most
robust genetic finding that alters the risk of developing
heavy smoking and nicotine addiction is in the chromo-
some 15q25 region, which contains the α5, α3, and β4 nic-
otinic receptor subunit gene cluster (CHRNA5, CHRNA3,
CHRNB4). The SNP rs16969968 is unequivocally associ-
ated with smoking behavior (p=5.6 × 10−72) (Tobacco
and Genetics Consortium 2010).
Fifteen GWASs of alcohol dependence and symptoms of
alcohol dependence, and nine studies of alcohol consump-
tion and other alcohol dependence related traits have to
date been published (Rietschel and Treutlein 2012). The
first GWAS on alcohol addiction (Treutlein et al. 2009)
and alcohol consumption (Schumann et al. 2011; Stacey
et al. 2012) yielded several genome-wide findings, especially
in the alcohol dehydrogenease (ADH) cluster (Frank
et al. 2012) and AUTS2 (Schumann et al. 2011) and were
replicated in independent studies (Biernacka et al. 2013
(ADH), Kapoor et al. 2013 (AUTS2)) (Figure 1).
Agrawal et al. (2011) reported the first genome-wide
association study (GWAS) of cannabis addiction in 708
cannabis dependent and more than 2000 control subjects.
None of the association signals reached genome-wide
significance most likely due to the small sample size. In
a larger study (Verweij et al. 2012) several previously
identified candidate genes for cannabis use were studied
in 7452 families from the Australian Twin Registry but
none of the 10 candidate genes were associated with
lifetime cannabis use. Very recently a meta-analysis with
more than 10,000 individuals was performed with again
no genome-wide findings. Even gene-based association
test in this large sample of cannabis abusers revealed no
significant effects of individual genes (Verweij et al. 2013).
However, it should be mentioned that the gene (CNR1)
that encodes the cannabinoid receptor 1 plays a moderate
role in modulating addictive behavior across several SUDs
(Benyamina et al. 2011).
Gelernter et al. (2013a) reported on the first GWAS in
opioid addicted patients with genome wide significant
findings with genes involved in potassium signaling path-
ways. Pathway analysis also implicated genes involved in
calcium signaling and long-term potentiation. The same
authors (Gelernter et al. 2013b) also reported on the first
GWAS in cocaine addiction in three sets of African- and
European-American subjects and identified several risk
variants. A first GWAS of pathological gambling was
also recently conducted (Lind et al. 2013). While further
replication is required, the identification of susceptibility
Figure 1 Genome wide significant findings for alcohol consumption and alcohol addiction. Alcohol metabolizing genes, especially in the
ADH cluster, are consistently found to be associated with alcohol addiction. Meta-analysis on large population based samples with almost 50,000
individuals demonstrated that a single nucleotide polymorphism (SNP) (rs6943555) in autism susceptibility candidate 2 gene (AUTS2) was associated
with alcohol consumption at genome-wide significance (Schumann et al. 2011). This finding was supported by multiple lines of evidence from mouse
and drosophila studies. Convergent evidence was also obtained for association of SNP rs26907 in the ras-specific guanine-nucleotide releasing factor 2
(RASGRF2) gene with alcohol consumption (Stacey et al. 2012). This finding was functionally validated in Rasgrf2 knockout mice – this is shown in the
lower panel where alcohol consumption in knockout and control littermate mice was measured in a drinkometer system (Vengeliene et al. 2013)
throughout day and night time. Rasgrf2 knockouts show completely blunted alcohol consumption confirming the human findings that RASGRF2 is
critically involved in regulating alcohol consumption (drinking data were kindly provided by Ainhoa Bilbao).
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izing the biological mechanisms that underpin pathological
gambling.
All GWAS-derived findings in addiction research are
summarized and constantly updated in the Addiction
GWAS Resource (AGR; addictiongwas.com; Spanagel et al.
(2013)). Although GWAS data sets are available now for
all different drug addictions and also for pathological
gambling, the data sets most likely do not contain enoughpower to estimate shared and distinct genetic components
for these disorders. Hence many more GWASs have to be
performed to make comparative analyses across different
SUDs, alcohol addiction and behavioral addictions.
Besides GWAS, genetic system-level approaches were
successfully used to estimate the overall effect of genetic
variations on a specific phenotype, for example within a
specific neurotransmitter system on alcohol drinking.
In particular, genetic system-level approaches in the
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Filbey et al. 2012), glutamatergic (Schumann et al. 2008;
Karpyak et al. 2012) and opioidergic (Levran et al. 2012;
Bazov et al. 2013) systems support a role of these neuro-
transmitter/peptide systems in both alcohol drinking and
addictive behavior. Those prior knowledge driven genetic
system-level approaches do not necessarily overlap with
gene network analyses which are used to find modules
of highly co-expressed genes with a gene of interest. The
generally held view is that genes which are associated or
interacting are more likely to share function and thereby
build up a network. However, this view seems to be the
exception rather than the rule in gene networks (Gillis
and Pavlidis 2012) since functional information within
gene networks is typically concentrated in only a very few
interactions whose properties cannot be reliably related
to the rest of the network. Thus gene function is not
necessarily encoded in a whole gene cluster.
Finally, SUDs and alcohol addiction are the result of
cumulative responses to drug/alcohol exposure, the genetic
make-up of an individual, and environmental perturbations
over time (Spanagel, 2009). Understanding how environ-
mental influences moderate genetic risk (gene x environ-
ment interactions; G x E) is crucial for the elucidation of
mechanisms underlying these disorders (Sher et al. 2010;
Spanagel et al. 2010; Yan et al. 2013). In the context of G x
E interactions, epigenetic mechanisms may also substan-
tially influence the initiation of addictive behavior, and
the first whole genome DNA methylation map has very
recently been obtained from alcohol-dependent patients
(Zhang et al. 2013) along with the demonstration of
elevated methylation in the brain of alcoholics (Taqi et al.
2011). Furthermore hypermethylation of genes (e.g. the
DAT gene locus) in alcohol-dependent patients seems to
be the consequence, rather than a cause, of the disorder
(Nieratschker et al. 2012).
In summary, although some genetic variants in candidate
genes have been convincingly identified by GWASs the
functional role of these gene variants in the development
and maintenance of addictive behavior, with some excep-
tions such as the alcohol metabolising ADH variants, are
poorly understood. Furthermore, only a small percentage
of the variation in drug / alcohol use initiation and addict-
ive behavior is due to common genetic variants and most
likely hundreds and more probably thousands of genetic
variants will be required to fully explain the genetic input
to drug addictions and behavioral addictions (Bierut 2011).
But even if we will identify by larger and larger samples
more and more risk variants we still do not understand
the interactions of these risk variants with environmental
factors such as stress and their epigenetic modulation
(Tsankova et al. 2007).
Here I propose to use a convergent functional genomics
(CFG) approach (Niculescu and Le-Niculescu 2010) withthe entire spectrum of state-of-the-art methodologies to
study the genetics of addictive behavior. Although a
CFG approach will not yield more candidate genes than
a classical GWAS it will provide convergent evidence
from several lines of genetic analysis – beyond the “p-value
hysteria and illusion” of human genetics today – to
functionally pin down in a convincing manner risk genes
and gene networks involved in addictive behavior. In the
following I will briefly outline in a general way the CFG
approach, and will then describe the “ingredients” for
future, hopefully successful CFG studies in the addiction
field.
The convergent functional genomics (CFG) approach
The term “convergent functional genomics” (CFG) has
been coined by Alexander B. Niculescu (Niculescu et al.
2000). It is an approach for identifying and prioritizing
candidate genes for complex psychiatric disorders (and
other diseases) by integrating multiple lines of evidence –
e.g. gene expression and genetic data from human studies
and animal model work. The more lines of evidence for
a gene, the higher it comes up on the CFG prioritization
list. This is similar conceptually to the Google PageRank
algorithm, in which the more links to a page the higher
it comes up on the search prioritization list. In a CFG
approach biologically-relevant signal even from limited
size studies are extracted and prioritized in a Bayesian
fashion. According to Bayesian theory, an optimal estimate
results from combining previous information with new
evidence. Although one cannot exclude that some of
the candidate genes that will be identified through this
approach are false positives because of potential biological
or technical limitations of the methodology and approach
employed, logically the higher the number of independent
lines of evidence (i.e. the higher the CFG score), the lower
the likelihood of that being the case. Thus at the end of
the day such an approach results in a polyevidence CFG
score. It is obvious that the way of weighing the lines of
evidence is on a subjective base (usually between 0.5-1
score per line of evidence) and may thereby give slightly
different results in terms of prioritization, if not in terms
of the list of genes per se (Niculescu and Le-Niculescu
2010). Nevertheless, the calculation of CFG scores for
example for schizophrenia (Ayalew et al. 2012), bipo-
lar disorder (Patel et al. 2010) and anxiety disorders
(Le-Niculescu et al. 2011) resulted in plausible and repro-
ducible ranked candidate gene lists.
What is important however is the functional valid-
ation of candidate genes. Here I propose to functionally
validate candidate genes by reverse genetics; i.e. to use a
conventional rodent knockout model that lacks the gene
of interest. More advanced transgenic models that lack
for example the gene of interest in a specific neuronal
population (Bilbao 2013) are less suited in this respect
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CFG approach is usually expressed in all cells. Alternatively
humanized rodent models can be used for validation. Here
the risk as well as the non-risk allele can be expressed in
the mouse or rat genome and then studied for their
drug-related phenotypes (Ramchandani et al. 2011) and
the development of addictive behavior. Compared to other
psychiatric research fields, drug addiction researchers are
in a good position to test those transgenic animals as
DSM-based animal models with excellent face, construct
and predictive validity are available (Sanchis-Segura and
Spanagel 2006; Cannella et al. 2013; Deroche-Gamonet
and Piazza 2013; Vengeliene et al. 2014).CFG application to addiction research – first step:
providing accumulated evidence for candidate genes
from forward genetics
Niculescu and collaborators also applied a CFG approach
to alcoholism (Rodd et al. 2007). In this study they
converged multiple independent internal (gene expression
profiling in genetically selected rats for high vs. low alcohol
preference) and external lines (mainly external databank
and literature-based information) of evidence for Bayesian
crossvalidation. Highest CFG scores where obtained for
alcohol metabolizing genes which is in line with GWAS
derived findings (see previous paragraph). Some of the
pathways identified in this study even suggest avenues
for pharmacotherapy of alcoholism with existing agents,
such as angiotensin-converting enzyme (ACE) inhibitors.
Indeed the authors could also show that an ACE inhibitor
results in strong modulation of alcohol intake in alcohol-
preferring rats (Rodd et al. 2007).
Convergent approaches were also used in other studies.
Although these approaches generated convergent evidence
from different human and animal data sets they did not
calculate a CFG score. One good example is the first
GWAS on alcohol addiction where the human data set
was combined with gene expression data that derived
from a DSM-based animal model which allows separating
alcohol addicted from non-addicted rats (Vengeliene et al.
2014). This combined data set was subjected to a replica-
tion study and eventually led to an enriched candidate gene
list (Treutlein et al. 2009).
As said, here I want to propose a CFG approach
based on the work of Alexander Niculesu and collaborators
that uses the entire spectrum of state-of-the-art methodolo-
gies of forward genetics. The repertoire of forward genetics
includes many different approaches and I will only refer to
some of them. Most straightforward in terms of forward
genetics is QTLb analysis in inbreed rodent strains, espe-
cially in recombinant strains (lines) combined with gene ex-
pression profiling (Spence et al. 2005; Crabbe et al. 2010).
This can be also done in genetically selected animals for aspecific phenotype, e.g. high vs. low drug consumption
(Spence et al. 2009; Crabbe et al. 2010).
A recombinant inbred strain (line) is an organism with
chromosomes that incorporate an essentially permanent set
of recombination events between chromosomes inherited
from two or more inbred strains. F1 and F2 generations are
produced by intercrossing the inbred strains; pairs of the F2
progeny are then mated to establish inbred strains through
long-term inbreeding. Families of recombinant inbred
are then used to map the locations of DNA sequence
differences (QTLs) that contribute to differences in a par-
ticular phenotype of interest; e.g. alcohol consumption.
The larger the family of recombinant inbred strains, the
greater the power and resolution with which phenotypes
can be mapped to chromosomal locations. Of particular
interest for addiction researchers is the BXD family of
recombinant inbred strains which was derived by crossing
C57BL/6J and DBA/2J and inbreeding progeny for 20
or more generations (www.genenetwork.org). With this re-
source data for hundreds of phenotypes have been acquired
over a nearly 40-year period. In particular, the BXD panel
is used to study the genetics of behavioral phenotypes of
alcohol and drug addiction, stress, and locomotor activity
(Hoffman et al. 2011; Wang et al. 2012). Another ad-
vantage of the BXD family of strains is that the both
parents have been sequenced and these two strains differ
at approximately 4.8 million SNPs (www.genenetwork.org).
Thus variants (mostly single nucleotide polymorphisms
and about 500,000 insertion-deletions) that produce inter-
esting phenotypes can be located efficiently. Importantly,
large gene expression data sets for different brain regions
of the BXD strains are also available (Wang et al. 2012).
This large database on BXD strains allows not only map-
ping new drug-related phenotypes to specific expression
QTLs but also to examine GWAS derived candidate genes.
Alternatively, genetically selected animals can be used
for combined QTL and expression analyses. In particular,
inbreed alcohol-preferring (iP) and -nonpreferring (iNP)
lines were developed from Wistar rats to model high and
low voluntary alcohol consumption, respectively and to
perform genetic studies (Crabbe et al. 2010). Using iP and
iNP strains, a strong QTL for alcohol consumption was
identified on rat chromosome 4 (Spence et al. 2009). To
search for candidate genes that underlie this chromosomal
region, complementary molecular-based strategies were
implemented to identify genetic targets that likely contrib-
ute to the linkage signal. Thus far, three candidate genes,
neuropeptide Y (NPY), alpha-synuclein, and corticotrophin-
releasing factor receptor 2, have been identified that may
account for the linkage signal (Spence et al. 2009). The
essential role of NPY in regulating alcohol consumption
and other alcohol-related behaviors has been convincingly
be demonstrated by the use of knockout and NPY overex-
pressing mice (Thiele et al. 1998; Hayes et al. 2012).
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are homozygous for a Grm2c stop codon that leads to
largely uncompensated loss of mGluR2 (Zhou et al. 2013).
In this study the stop codon variation was linked to
increased alcohol consumption and preference in F2
rats generated by intercrossing iP and iNP rats. The causal
role of mGluR2 in altered alcohol preference was finally
confirmed by elevated alcohol consumption in Grm2
knockout mice. Interestingly, in the brain of alcoholic
patients a strong down-regulation of Grm2 transcripts
has also been found (Meinhardt et al. 2013). Together,
these data point to mGluR2 as an origin of alcohol prefer-
ence and a potential therapeutic target and demonstrate
how powerful genetic analysis in inbred alcohol preferring
animals can be.
Gene expression profiling studies in brain areas which
are of relevance for mediating alcohol and drug-induced
effects such as reinforcement (Noori et al. 2012) in DSM-
based animal models can also yield candidate gene lists
that can be used for CFG scoring. For example gene
expression profiling in the dorsal striatum of alcohol
addicted vs. non-addicted rats showed an up-regulation of
dopamine D3 receptor transcripts and in a series of
follow-up studies the critical role of D3 receptors in
addictive behavior was confirmed (Vengeliene et al. 2006;
Song et al. 2012; Xi et al. 2013).
Beside the here described forward genetic approaches
other omics based approaches and in particular proteomics
(Wang et al. 2011) can be used to achieve convergent evi-
dence for the role of a particular gene in a drug-related
phenotype of interest. These lines of evidence derived from
animal work can be used to calculate a CFG score without
giving any particular weight to one or another approach;
i.e. each line of evidence for a particular gene of interest
would be scored by one. This animal research based
CFG score would then be added to the lines of evidence
obtained on the human side. Here as already mentioned
linkage data, GWAS data, gene expression data from
brain and other tissues, and also proteomics data can
provide in addition to the animal data polyevidence for a
gene/gene product of interest. In conclusion, candidate
genes derived from a CFG approach can be categorized
according to their CFG score into top candidate genes
and categories of less importance.
Second step: functional validation of candidate genes
by reverse genetics
It is increasingly evident that functional validation of the
role of genes identified by forward genetic models is a
critical step of strengthening the case for a causal relation-
ship between the gene and the observed phenotype. One
way of validation is to manipulate the gene using reverse
genetics and test the manipulated animals in behavioral
tests or models (Sanchis-Segura and Spanagel 2006). Thechoice of strategy for doing this may depend on a lot of
factors such as the level of existing knowledge about
the gene. One important issue is the choice of species.
In a bigger perspective this is often a tradeoff between
similarity to humans and practical issues regarding
maintaining the species in an animal facility (size, length of
reproductive cycle, aggressiveness and cost). A particular
important question in the context of reverse genetics is
also the availability of genetic models in the chosen species.
Today, the mouse is the standard species for studying
drug addiction with reverse genetics. However, rats are
becoming increasingly popular and this trend will most
likely continue since it seems like the rat is a better
choice for complicated long-term models of addiction
(Kasanetz et al. 2013; Cannella et al. 2013; Vengeliene
et al. 2014). Further, several genetic techniques now can
be used in the rat (Geurts et al. 2009; Tong et al. 2010;
Brown et al. 2013). However, the mouse still has the advan-
tages of the plethora of lines available, a more widespread
availability of facilities and laboratories with the capacity
to generate mutant lines and the lower cost per animal
(which is a critical factor in models requiring a lot of
breeding).
Reverse genetics can be broadly divided into approaches
resulting in random integration of transgenes and targeted
approaches. The first category includes “classic” transgenes
introduced by pronuclear injection and a variety of
viral-mediated techniques. These approaches have the
advantage of being relatively rapid. The use of constructs
based on bacterial artificial chromosomes has become
increasingly popular during the last decade since it makes
the expression of transgenes made by pronuclear injection
much more reliable (Heintz 2001). The targeted approaches
include the generation of knockout and knockin animals.
The latter is particularly interesting as a functional valid-
ation of data from humans (e.g. GWAS data) since it can
be used to modify an allele in the mouse to mimic an allele
known to affect the risk of a specific phenotype in man.
Expression of dominant negative molecules is another
alternative for inhibiting the function of certain molecules
(Heusner and Palmiter 2005). This approach can also be
used to silence families of molecules (e.g. an ion channels
subunit engineered to block the pore will block all channels
where it is integrated independent of subunit composition).
Another way of silencing genes is the use of gene-targeted
zinc finger nucleases. This methodology has been used
to inactivate genes in a sequence specific manner in the
rat (Geurts et al. 2009). Recently, it has also been used to
mediate homologous recombination in mouse zygotes,
showing that it has potential beyond simple inactivation
(Meyer et al. 2010). Another interesting resource is
repositories with ES cell lines in which genes have been
inactivated by gene trapping (Guan et al. 2010). Gene
trapping has also been used to generate conditional
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to gene trap based repositories there are other initiatives
for providing researchers with classic knockout mice and
mice with conditional mutations on a genome-wide level
(Guan et al. 2010). Together with the accumulating num-
ber of mutant mice generated by research groups all over
the world it will be much easier to find already existing
mutant mice for studying the candidate gene of interest.
Conclusion
GWASs in the addiction field provided first interesting
insights into the genes that drive, at least in part, a
drug-related phenotype. However, given that much of
the variance is driven by societal, lifestyle and behavioral
influences - and in addition there are also problems
related to DSM-based diagnostic criteria (Miller 2010) -
larger sample sizes for GWA analysis, inclusion of endo-
phenotypes and CFG approaches are warranted. Having
already massive transcriptomic, genetic and phenotypic
datasets available a Bayesian-like integration strategy can
be applied where multiple independent lines of genetic
and genomic evidence is used, each by itself lacking
sufficient discriminatory power, but combined leads to
the identification of high probability candidate genes or
gene clusters. The role in the etiology of addiction of these
high probability candidate genes or gene clusters and their
interaction with environmental factors will have to be
finally validated in appropriate knockout and humanized
animal models.
Endnotes
aThe term “drug addictions” used in this review is the
same as the DSM-5 term “substance use disorders”.
bA mapped QTL defines the location of a gene (or more
than one gene) that influences a complex trait (i.e., one
that is influenced by multiple genes, by environmental
factors and can be influenced by all possible interactions
of these variables).
cGrm2 encodes metabotropic glutamate receptor 2
(mGluR2) which is critically involved in regulating extra-
synaptic glutamate levels.
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